Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

Autor: Jeffrey N. Weitzel, David R. Gandara, Edward M. Newman, Christopher Ruel, Alice P. Chen, Katherine V. Ferry-Galow, Lily R. Van Tongeren, Josef Herzog, Sharon Sand, Richard Piekarz, Joanne Mortimer, Arti Hurria, Jan H. Beumer, Matthew P. Goetz, Linda T. Vahdat, Timothy J. Moynihan, Helen K. Chew, Rita Nanda, Joseph A. Sparano, Harold A. Harvey, Leah V. Cream, Tessa Cigler, Agustin A. Garcia, Cynthia X. Ma, Banu K. Arun, Paul H. Frankel, George Somlo
Rok vydání: 2023
Popis: Veliparib pharmacokinetics with geometric mean* and standard deviation (SD) plasma pharmacokinetic parameters during the phase I combination phase
Databáze: OpenAIRE